226 related articles for article (PubMed ID: 22038453)
1. The use of combination therapy in the treatment of postmenopausal osteoporosis.
Compston J
Endocrine; 2012 Feb; 41(1):11-8. PubMed ID: 22038453
[TBL] [Abstract][Full Text] [Related]
2. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.
Middleton ET; Steel SA; Aye M; Doherty SM
Osteoporos Int; 2012 Jan; 23(1):295-303. PubMed ID: 21274515
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
Gallacher SJ; Dixon T
Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
[TBL] [Abstract][Full Text] [Related]
4. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
Middleton ET; Steel SA; Aye M; Doherty SM
J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
[TBL] [Abstract][Full Text] [Related]
5. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
Cosman F
Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
[TBL] [Abstract][Full Text] [Related]
6. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
7. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
Quesada-Gómez JM; Muschitz C; Gómez-Reino J; Greisen H; Andersen HS; Dimai HP
Osteoporos Int; 2011 Sep; 22(9):2529-37. PubMed ID: 21052638
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
Schafer AL; Burghardt AJ; Sellmeyer DE; Palermo L; Shoback DM; Majumdar S; Black DM
Osteoporos Int; 2013 Oct; 24(10):2591-601. PubMed ID: 23589163
[TBL] [Abstract][Full Text] [Related]
9. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
12. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
Adami S
Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
[TBL] [Abstract][Full Text] [Related]
13. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
14. [Impacts on bone mineral density].
Kurth A
Orthopade; 2014 Feb; 43(2):182. PubMed ID: 24693554
[No Abstract] [Full Text] [Related]
15. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
16. Effects of anti-resorptive agents on trabecular bone score (TBS) in older women.
Krieg MA; Aubry-Rozier B; Hans D; Leslie WD;
Osteoporos Int; 2013 Mar; 24(3):1073-8. PubMed ID: 23052939
[TBL] [Abstract][Full Text] [Related]
17. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
Schafer AL; Sellmeyer DE; Palermo L; Hietpas J; Eastell R; Shoback DM; Black DM
J Clin Endocrinol Metab; 2012 Oct; 97(10):3522-9. PubMed ID: 22791766
[TBL] [Abstract][Full Text] [Related]
18. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
19. Combination of Micronutrients for Bone (COMB) Study: bone density after micronutrient intervention.
Genuis SJ; Bouchard TP
J Environ Public Health; 2012; 2012():354151. PubMed ID: 22291722
[TBL] [Abstract][Full Text] [Related]
20. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
